Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma

Journal of Immunotherapy

Volumn 38, Issue 8, 2015, Pages 330-339

  Nguyen Pham, Thanh Nhan ^a,b   Jung, Sung Hoon ^a,b   Vo, Manh Cuong ^a   Thanh Tran, Huong Thi ^b   Lee, Youn Kyung ^c   Lee, Hyun Ju ^a   Choi, Nu Ri ^a   Hoang, My Dung ^a   Kim, Hyeoung Joon ^b   Lee, Je Jung ^a,b,c  

^a Research Center for Cancer Immunotherapy   (United States)

^b Chonnam National University Research Institute of Medical Sciences   (South Korea)

^c Vaxcell Bio Therapeutics   (South Korea)

Author keywords

dendritic cells; lenalidomide; multiple myeloma

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; INTERLEUKIN 10; LENALIDOMIDE; TUMOR ANTIGEN; ANGIOGENESIS INHIBITOR; CANCER VACCINE; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL FUNCTION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SUPPRESSOR CELL; TH1 CELL; TH1 TH2 BALANCE; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; MICE, INBRED BALB C; MULTIPLE MYELOMA; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; THALIDOMIDE;

EID: 84941947121     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000097     Document Type: Article

References (40)

1. Oden F, Marino SF, Brand J, et al. Potent anti-Tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma. Mol Oncol. 2015;9:1348-1358.
2. Kumar SK, Gertz MA. Risk adapted therapy for multiple myeloma: back to basics. Leuk Lymphoma. 2014;55:2218-2220.
3. Tucci M, Stucci S, Strippoli S, et al. Dendritic cells and malignant plasma cells: An alliance in multiple myeloma tumor progression? Oncologist. 2011;16:1040-1048.
4. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrowderived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297-1302.
5. Wen YJ, Ling M, Bailey-Wood R, et al. Idiotypic proteinpulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998;4:957-962.
6. Röllig C, Schmidt C, Bornhaüser M, et al. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother. 2011;34:100-106.
7. Nguyen-Pham TN, Lee YK, Kim HJ, et al. Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol. 2012;2012:397648.
8. Channan-Khan AA, San Miguel JF, Jagannath S, et al. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18:2145-2163.
9. Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27:1704-1714.
10. Parrish C, Scott GB, Cook G. Immune dysfuction in multiple myeloma. Int J Hematol Oncol. 2013;2:49-59.
11. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood. 2002;100:230-237.
12. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
13. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142.
14. Dimopoulos MA, Chen C, Spencer A, et al. Long-Term followup on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23: 2147-2152.
15. Lagrue K, Carisey A, Morgan DJ, et al. Lenalidomide augments actin remodelling and lowers NK cell activation thresholds. Blood. 2015;126:50-60.
16. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759-1769.
17. Qiao SK, Guo XN, Ren JH, et al. Efficacy and safety of lenalidomide in the treatment of multiple myeloma: A systematic review and meta-Analysis of randomized controlled trials. Chin Med J (Engl). 2015;128:1215-1222.
18. Reddy N, Hernandez-llizalituri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-Tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36-45.
19. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58:1033-1045.
20. Luptakova K, Glotzbecker B, Mills H, et al. 492 Lenalidomide decrease PD-1 expression, depletes regulatory T-cells and improves cellular response to a multiple myeloma/Dendritic cell fusion vaccine in vitro. 53rd ASH Annual Meeting and exposition. 2011.
21. Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013;62:39-49.
22. Nguyen Pham TN, Hong CY, Min JJ, et al. Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist. Exp Mol Med. 2010;42:407-419.
23. Yurchenko E, Shio MT, Huang TC, et al. Inflamation-driven reprogramming of CD4+Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PloS One. 2012;7:e35572.
24. Madireddi S, Schabowsky RH, Srivastava AK, et al. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+FoxP3+ T regulatory cells by production of IFN-g. PLoS One. 2012;7:e42459.
25. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis. Genes Cancer. 2011;2:1097-1105.
26. Niu G, Chen X. Vascular endothelial growth factor as an antiangiogenic target for cancer therapy. Curr Drug Targets. 2010;11:1000-1017.
27. Kwon YW, Heo SC, Jeong GO, et al. Tumor necrosis factor-Aactivated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. Biochim Biophys Acta. 2013;1832:2136-2144.
28. Liu WM, Henry JY, Meyer B, et al. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer. 2009;101: 803-812.
29. Liu WM, Laux H, Henry JY, et al. A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Mol Biol Rep. 2010;37:1801-1814.
30. Henry JY, Lu L, Adams M, et al. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate. 2012;72:856-867.
31. Jungkunz-Stier I, Zekl M, Stühmer T, et al. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells. Leuk Lymphoma. 2014;55:168-176.
32. Xu Y, Sun J, Sheard MA, et al. Lenalidomide overcomes suppression of human natural killer cell anti-Tumor functions by neuroblastoma microenvironment-Associated IL-6 and TGFb1. Cancer Immunol Immunother. 2013;62:1637-1648.
33. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128: 192-203.
34. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117:1605-1613.
35. Haslett PA, Hanekom WA, Muller G, et al. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis. 2003;187:946-955.
36. Henry JY, Labarthe MC, Meyer B, et al. Enhanced crosspriming of naive CD8+ T cells by dendritic cells treated by the IMiDs immunomodulatory compounds lenalidomide and pomalidomide. Immunology. 2013;139:377-385.
37. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 2011;71:5101-5110.
38. Brimnes MK, Vangsted AJ, Knudsen LM, et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLADR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010;72:540-547.
39. Yu P, Rowley DA, Fu YX, et al. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol. 2006;18:226-231.
40. Valzasina B, Piconese S, Guiducci C, et al. Tumor-induced expansion of regulatory T cells by conversion of CD4+ CD25 lymphocytes is thymus and proliferation independent. Cancer Res. 2006;66:4488-4495.